Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human galectin-8
- Development stage
- Preclinical
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Recombinant human galectin-8 (rhGal-8) is a laboratory-produced version of the human galectin-8 protein, which belongs to the tandem-repeat galectin family. It is characterized by two carbohydrate-recognition domains that specifically bind to i-linear poly-N-acetyllactosamines (poly-LacNAc) on cell surfaces. In the context of cancer research, rhGal-8 is used as a research reagent to investigate the molecular mechanisms of tumor cell adhesion and metastasis. Studies have demonstrated that rhGal-8 can bridge melanoma cells to the vascular endothelium, thereby facilitating systemic dissemination. While rhGal-8 is primarily a research tool, the Gal-8/poly-LacNAc axis is being explored as a potential therapeutic target for the development of anti-metastatic agents.
- Other names
- Galectin-8Galectin8Galectin 8LGALS8LGALS-8LGALS 8
02
Targets
CD44 (CD44 antigen)3'-O-sialylated and 3'-O-sulfated β-galactoside glycansIntegrin beta-1 bearing alpha-2,3-sialylated glycansTF antigen (Thomsen-Friedenreich antigen)poly-LacNAc (Linear poly-N-acetyllactosamine)
Beyond the preview
Go deeper on recombinant human galectin-8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human galectin-8.